Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
<p>Choroideremia is a rare, X-linked retinal degeneration resulting in progressive vision loss. A randomized, masked, phase 3 clinical trial evaluated the safety and efficacy over 12 months of follow-up in adult males with choroideremia randomized to receive a high-dose (1.0&thi...
主要な著者: | MacLaren, RE, Fischer, MD, Gow, JA, Lam, BL, Sankila, E-MK, Girach, A, Panda, S, Yoon, D, Zhao, G, Pennesi, ME |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Springer Nature
2023
|
類似資料
-
Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
著者:: Han, RC, 等
出版事項: (2021) -
Recent advances and future prospects in choroideremia
著者:: Zinkernagel MS, 等
出版事項: (2015-11-01) -
Macular hole surgery in patients with end-stage choroideremia
著者:: Zinkernagel, MS, 等
出版事項: (2013) -
Functional defects in color vision in patients with choroideremia
著者:: Jolly, J, 等
出版事項: (2015) -
Choroideremia: molecular mechanisms and development of AAV gene therapy
著者:: Patrício, M, 等
出版事項: (2018)